Öğr. Gör. Dr. DENİZ CANSEN KAHRAMAN

Yayın Ağı

Makaleler 24

1. Target-specific de novo design of drug candidate molecules with graph-transformer-based generative adversarial networks

Ünlü A., Çevrim E., Yiğit M. G., Sarıgün A., Çelikbilek H., Bayram O., et al.

Nature Machine Intelligence , cilt.7, sa.9, ss.1524-1540, 2025 (SCI-Expanded, Scopus)

2. Design, synthesis, and evaluation of novel Indole-Based small molecules as sirtuin inhibitors with anticancer activities.

Binarci B., Kilic E. K., Dogan T., Cetin Atalay R., Kahraman D. C., Nacak Baytas S.

Drug development research , cilt.85, sa.7, 2024 (SCI-Expanded, Scopus)

3. Design, synthesis, molecular docking studies and biological evaluation of thiazole carboxamide derivatives as COX inhibitors

Hawash M., Jaradat N., Abualhasan M., ŞÜKÜROĞLU M. K., Qaoud M. T., KAHRAMAN D. C., et al.

BMC Chemistry , cilt.17, sa.1, 2023 (SCI-Expanded, Scopus)

4. Novel indole-pyrazole hybrids as potential tubulin-targeting agents; Synthesis, antiproliferative evaluation, and molecular modeling studies

Hawash M., Ergun S. G., KAHRAMAN D. C., OLĞAÇ A., Hamel E., Cetin-Atalay R., et al.

Journal of Molecular Structure , cilt.1285, 2023 (SCI-Expanded, Scopus)

5. A new triazolothiadiazine derivative inhibits stemness and induces cell death in HCC by oxidative stress dependent JNK pathway activation

KAHRAMAN D. C., Guven E. B., Aytac P. S., Aykut G., Tozkoparan B., Atalay R. C.

SCIENTIFIC REPORTS , cilt.12, sa.1, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

6. Design and synthesis of novel substituted indole-acrylamide derivatives and evaluation of their anti-cancer activity as potential tubulin-targeting agents

Hawash M., KAHRAMAN D. C., OLĞAÇ A., Ergun S. G., Hamel E., Cetin-Atalay R., et al.

JOURNAL OF MOLECULAR STRUCTURE , cilt.1254, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

7. Low Density Granulocytes and Dysregulated Neutrophils Driving Autoinflammatory Manifestations in NEMO Deficiency

Yilmaz N. S., Eltan S. B., KAYAOĞLU B., Geckin B., Heredia R. J., Sefer A. P., et al.

JOURNAL OF CLINICAL IMMUNOLOGY , cilt.42, sa.3, ss.582-596, 2022 (SCI-Expanded, Scopus)

8. Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.

Narci K., Kahraman D. C., Koyas A., Ersahin T., Tuncbag N., Atalay R. C.

BMC cancer , cilt.22, sa.1, ss.320, 2022 (SCI-Expanded, Scopus)

9. Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines

Hawash M., KAHRAMAN D. C., Ergun S. G., Cetin-Atalay R., BAYTAŞ S.

BMC CHEMISTRY , cilt.15, sa.1, 2021 (SCI-Expanded, Scopus)

10. Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools

Cetin-Atalay R., Kahraman D. C., Nalbat E., Rifaioğlu A. S., Atakan A., Dönmez A., et al.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.52, sa.4, ss.1266-1276, 2021 (ESCI, Scopus)

11. Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells

Ibis K., NALBAT E., ÇALIŞKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĞLU E.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.221, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Novel Indolylacrylamide Derivatives: Synthesis and Biological Evaluation

Hawash M., Kahraman D. C., Cetin-Atalay R., BAYTAŞ S.

CHEMISTRY & BIODIVERSITY , cilt.18, sa.5, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

13. MDeePred: Novel multi-channel protein featurization for deep learning-based binding affinity prediction in drug discovery

Rifaioglu A., Atalay R. C., KAHRAMAN D. C., DOĞAN T., Martin M., ATALAY M. V.

Bioinformatics , cilt.37, sa.5, ss.693-704, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. Transcriptome profiles associated with selenium-deficiency-dependent oxidative stress identify potential diagnostic and therapeutic targets in liver cancer cells

Gozen D., KAHRAMAN D. C., Narci K., Shehwana H., KONU KARAKAYALI Ö., Cetin-Atalay R.

TURKISH JOURNAL OF BIOLOGY , cilt.45, sa.2, ss.149-164, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

15. CXXC5 as an unmethylated CpG dinucleotide binding protein contributes to estrogen-mediated cellular proliferation.

Ayaz G., Razizadeh N., Yaşar P., Kars G., Kahraman D. C., Saatci Ö., et al.

Scientific reports , cilt.10, ss.5971, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

16. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment

KAHRAMAN D. C., Kahraman T., Cetin-Atalay R.

MOLECULAR CANCER THERAPEUTICS , cilt.18, sa.11, ss.2146-2157, 2019 (SCI-Expanded, Scopus)

17. Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.

Ture A., Kahraman D. C., Cetin-Atalay R., Helvacioglu S., Charehsaz M., KÜÇÜKGÜZEL İ.

Computational biology and chemistry , cilt.78, ss.227-241, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

18. Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents.

Inceler N., ÖZKAN Y., Turan N. N., Kahraman D. C., Cetin-Atalay R., BAYTAŞ S.

MedChemComm , cilt.9, sa.5, ss.795-811, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.

Hawash M. M. A., Kahraman D. C., Eren F., Atalay R. C., BAYTAŞ S.

European journal of medicinal chemistry , cilt.129, ss.12-26, 2017 (SCI-Expanded, Scopus)

20. Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.

Kahraman D. C., Hanquet G., Jeanmart L., Lanners S., Sramel P., Bohac A., et al.

MedChemComm , cilt.8, sa.1, ss.81-87, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

21. Phase and TV Based Convex Sets for Blind Deconvolution of Microscopic Images

Tofighi M., Yorulmaz O., Koese K., Yildirim D. C., Cetin-Atalay R., ÇETİN A. E.

IEEE JOURNAL OF SELECTED TOPICS IN SIGNAL PROCESSING , cilt.10, sa.1, ss.81-91, 2016 (SCI-Expanded, Scopus)

22. Ynamide Click chemistry in development of triazole VEGFR2 TK modulators.

Vojtickova M., Dobias J., Hanquet G., Addova G., Cetin-Atalay R., Yildirim D. C., et al.

European journal of medicinal chemistry , cilt.103, ss.105-22, 2015 (SCI-Expanded, Scopus)

23. Application of the Ugi reaction with multiple amino acid-derived components: synthesis and conformational evaluation of piperazine-based minimalist peptidomimetics.

Stucchi M., Cairati S., Cetin-Atalay R., Christodoulou M. S., Grazioso G., Pescitelli G., et al.

Organic & biomolecular chemistry , cilt.13, sa.17, ss.4993-5005, 2015 (SCI-Expanded, Scopus)

24. Near-IR absorbing BODIPY derivatives as glutathione-activated photosensitizers for selective photodynamic action.

Turan I., Cakmak F., Yildirim D. C., Cetin-Atalay R., Akkaya E.

Chemistry (Weinheim an der Bergstrasse, Germany) , cilt.20, ss.16088-92, 2014 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 33

1. Unveiling Molecular Biomarkers of MASLD Fibrosis: A Transcriptomic and Pathway Enrichment Analysis

NALBAT E., KAHRAMAN D. C.

AASLD-TASL Hepatology Connect Meeting 2025, İstanbul, Türkiye, 14 - 15 Şubat 2025, (Özet Bildiri)

2. Deciphering Transcriptional Landscapes of Mild and Advanced MASLD Fibrosis: Insights into Differential Gene Expression, Pathway Enrichment, and Drug Repurposing Opportunities

NALBAT E., KAHRAMAN D. C.

17th International Symposium on Health Informatics and Bioinformatics, İstanbul, Türkiye, 18 - 20 Aralık 2024, (Özet Bildiri)

3. Targeting sirtuins with novel indole derivatives: implications for anticancer activity in hepatocellular carcinoma

BINARCI B., DOĞAN T., ATALAY R., KAHRAMAN D. C., BAYTAŞ S.

EASL Liver Cancer Summit 2024, Rotterdam, Hollanda, 22 - 24 Şubat 2024, (Özet Bildiri)

4. Exploring early markers of fibrosis progression in metabolic dysfunction–associated steatotic liver disease in Turkiye

KAHRAMAN D. C., NALBAT E., ATALAY R., İDİLMAN R.

AASLD-TASL Connect Meeting 2024, İzmir, Türkiye, 16 - 17 Şubat 2024, (Özet Bildiri)

5. Repurposing Drugs to Target Molecular Networks in Hepatocellular Carcinoma Cells & Stem Cells for Innovative Treatment Strategies

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

4th Open Research Day, Türkiye, 01 Aralık 2023, (Özet Bildiri)

6. DeepResponse: Large Scale Prediction of Cancer Cell Line Drug Response with Deep Learning Based Pharmacogenomic Modelling

KAHRAMAN D. C., DOĞAN T.

16th International Symposium on Health Informatics and Bioinformatics (HIBIT 2023), Ankara, Türkiye, 4 - 06 Ekim 2023, (Özet Bildiri)

7. Anti-Cancer and Anti-Stemness Action of Nonsteroidal Anti-Inflammatory Agents: A Special Focus on Hepatocellular Carcinoma

KAHRAMAN D. C.

3rd International Multidisciplinary Cancer Research Congress, İstanbul, Türkiye, 7 - 10 Eylül 2023, (Özet Bildiri)

8. Network-based drug repurposing approach identifies novel drugs and drug combinations against HCC

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

AASLD-TASL Digital Hepatology Meeting, Ankara, Türkiye, 28 - 29 Nisan 2023, (Özet Bildiri)

9. Experimental validation of drug responses predicted by deep learning-based bioactivity models in hepatocellular carcinoma cell lines

KAHRAMAN D. C., DOĞAN T.

15th International Symposium on Health Informatics and Bioinformatics (HIBIT 2022), Mersin, Türkiye, 20 - 22 Ekim 2022, (Özet Bildiri)

10. A Multi-Omics and Machine Learning-Based Predictor of Drug Sensitivity in Cancer

KAHRAMAN D. C., DOĞAN T.

15th International Symposium on Health Informatics and Bioinformatics (HIBIT 2022), Mersin, Türkiye, 20 - 22 Ekim 2022, (Özet Bildiri)

11. Automated prediction of drug response in HCC cell lines with deep learning-based bioactivity modeling and experimental validation

KAHRAMAN D. C., AKAR E., DOĞAN T.

EACR 2022, Sevilla, İspanya, 20 - 23 Haziran 2022, (Özet Bildiri)

12. Synergistic effect of sorafenib in combination with naproxen on hepatocellular carcinoma cell lines

AKAR E., KAHRAMAN D. C.

EACR 2022, Sevilla, İspanya, 20 - 23 Haziran 2022, (Özet Bildiri)

13. A NEW THIADIAZINE DERIVATIVE INDUCES OXIDATIVE STRESS DEPENDENT CELL DEATH IN HEPATOCELLULAR CARCINOMA STEM CELLS

KAHRAMAN D. C., GÜVEN E. B., Aytac P., TOZKOPARAN KÖPRÜCÜ B., ATALAY R.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)

14. In silico modeling and in vitro validation of undefined off-target of drugs in hepatocellular carcinoma

Sinoplu E., Tuncbag N., Kahraman D. C., Atalay R. C.

Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019, cilt.79, (Özet Bildiri)

15. A new thiadiazine derivative induces oxidative stress dependent JNK pathway activation and cell death in hepatocellular carcinoma

KAHRAMAN D. C., GÜVEN E. B., TOZKOPARAN KÖPRÜCÜ B., ATALAY R.

Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019, cilt.79, (Özet Bildiri)

16. Abstract 996: In silico modeling and in vitro validation of undefined off-target of drugs in hepatocellular carcinoma

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

AACR Annual Meeting 2019, Atlanta, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019, (Özet Bildiri)

17. Effects of small molecule inhibitors on liver cancer stem cells in comparison with Sorafenib

KAHRAMAN D. C., ATALAY R.

AASLD-TASL Connect Meeting 2019, İstanbul, Türkiye, 15 - 16 Mart 2019, (Özet Bildiri)

18. Identification of interleukin 8 as a cancer stem cell enrichment stimulating factor in HCC

KAHRAMAN D. C., ATALAY R.

11th International Symposium on Health Informatics and Bioinformatics (HIBIT 2018), Antalya, Türkiye, 25 - 27 Ekim 2018, (Özet Bildiri)

19. Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib

Kahraman D. C., Kahraman T., ATALAY R.

American Association for Cancer Research Annual Meeting 2018, Chicago, Amerika Birleşik Devletleri, 12 - 18 Nisan 2018, cilt.78, ss.3937, (Özet Bildiri) Sürdürülebilir Kalkınma

20. Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells

KAHRAMAN D. C., ATALAY R.

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Philadelphia, Amerika Birleşik Devletleri, 26 - 30 Ekim 2017, (Özet Bildiri)